ArticleOpen veterinary journal2025
Triple-phase contrast-enhanced computed tomography findings in dogs with cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: Pilot study.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Imaging Characterization of a Cystic Duct Neuroendocrine Carcinoma in a Dog Using Contrast-Enhanced Ultrasonography and Multiphasic Computed Tomography.Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recently, the usefulness of triple-phase contrast-enhanced computed tomography (CT) scans for liver tumors in canines has been reported. However, detailed information on the CT findings of cholangiocarcinoma (CCA) and combined hepatocellular-cholangiocarcinoma (cHCC-CCA) remains limited. Aim: This study aimed to retrospectively evaluate triple-phase contrast-enhanced CT findings in canine CCA and cHCC-CCA using objective parameters, such as CT values and morphological characteristics. Methods: This study included eight dogs that underwent triple-phase contrast-enhanced CT scans and surgical removal and were pathologically diagnosed. Three CCA cases and five cHCC-CCA cases were analyzed. Parameters included CT values and mass sizes, CT values and lymph node sizes, and rim enhancement. "Rim enhancement" was defined as the contrast enhancement effect at the liver parenchyma-mass boundary. Results: CT values for CCA were as follows: pre-contrast: 43.9 ± 3.6 Hounsfield units (HUs); arterial phase: 76.9 ± 22.5 HU; portal phase: 98.8 ± 37.7 HU; equilibrium phase: 90.9 ± 27.1 HU. For cHCC-CCA, the mean CT values were as follows: pre-contrast: 50.7 ± 6.1 HU; arterial phase: 80.2 ± 19.2 HU; portal phase: 95.0 ± 21.3 HU; equilibrium phase: 86.1 ± 13.4 HU. The peak contrast enhancement for both CCA and cHCC-CCA was in the portal phase. Rim enhancement appeared in the arterial phase in all CCA cases, whereas it appeared in the portal phase in 80% of cHCC-CCA cases, indicating a significant difference. Conclusion: Rim enhancement may help distinguish between CCA and cHCC-CCA. However, this study has a limited number of cases, and future large-scale, multicenter studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.